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ABSTRACT 23 
Background: Emerging evidence suggests that maternal folate status can impact cognitive 24 
development in childhood. Folate-dependent DNA methylation may provide a biological 25 
mechanism to link folate status during pregnancy with cognition in the offspring.  26 
Objective: The objective was to investigate the effect of continued folic acid (FA) 27 
supplementation beyond the first trimester of pregnancy on DNA methylation in cord blood 28 
of epigenetically-controlled genes related to brain development and function.  29 
Design: Using available cord blood samples (n = 86) from the Folic Acid Supplementation in 30 
the Second and Third Trimesters (FASSTT) trial in pregnancy, we applied pyrosequencing 31 
techniques to analyze cord blood DNA at nine candidate loci known to be regulated by 32 
methylation including some previously implicated in observational studies: the widely-33 
dispersed retrotransposon LINE-1 and eight single-copy loci (RBM46, PEG3, IGF2, GRB10, 34 
BDNF, GRIN3B, OPCML and APC2).  35 
Results: The newborns of mothers who received FA (400 µg/d) during pregnancy, compared 36 
to placebo, had significantly lower overall DNA methylation levels at LINE-1 (57.2 ± 2.1 % 37 
vs 56.3 ± 1.7 %; P = 0.024), IGF2 (51.2 ± 5.1 % vs 48.9 ± 4.4 %; P = 0.021) and BDNF (3.1 38 
± 0.8 % vs 2.7 ± 0.7 %; P = 0.003). The effect of FA treatment on DNA methylation was 39 
significant only in female offspring for IGF2 (P = 0.028) and only in males for BDNF (P = 40 
0.012). For GRB10 and GRIN3B, we detected no effect on overall methylation, however, 41 
individual CpG sites showed significant DNA methylation changes in response to FA.  42 
Conclusions: Continued supplementation with FA through trimesters 2 and 3 of pregnancy 43 
results in significant changes in DNA methylation in cord blood of genes related to brain 44 
development. The findings offer a potential biological mechanism linking maternal folate 45 
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status with neurodevelopment of the offspring, but this requires further investigation using a 46 
genome-wide approach.  47 
The FASSTT trial is registered at: www.isrctn.com/ISRCTN19917787. 48 
 49 
Key words: Folic acid, Pregnancy, DNA methylation, Epigenetics   50 
4 
 
 
 
INTRODUCTION  51 
 Periconceptional folic acid (FA) supplementation has a proven effect in preventing the 52 
first occurrence (1) and recurrence (2) of neural tube defects (NTD). As a result, women 53 
planning a pregnancy are recommended to take 400 μg/d FA from preconception until the end 54 
of the first trimester (3). Apart from preventing NTD in early pregnancy, emerging evidence 55 
shows that maternal folate status may have other roles in offspring health, particularly in 56 
relation to cognitive development in childhood (4, 5). Several observational studies have 57 
identified a potential role of maternal folate status during pregnancy on the cognitive 58 
performance of offspring (6, 7, 8). We previously investigated the children of mothers who 59 
had participated in a randomized trial in pregnancy of Folic Acid Supplementation in the 60 
Second and Third Trimesters (FASSTT) (9) and, in a preliminary publication, found 61 
beneficial effects of FA on cognition in children at age 3 and 6 years (10). Although, the 62 
precise biological mechanism explaining the effect of FA during pregnancy on 63 
neurodevelopment of the child is unknown, it must involve the essential role of folate in one-64 
carbon metabolism, whereby one-carbon units are transferred and utilized in critical pathways 65 
involving amino acid metabolism, biosynthesis of purines and pyrimidines and the 66 
methylation of biological substrates including DNA.  67 
Epigenetics refers to heritable changes in gene expression, which occur without 68 
altering the underlying DNA sequence, often via histone modification, RNA interference or 69 
DNA methylation (11).  DNA methylation is the most widely studied epigenetic mechanism 70 
for gene regulation and is dependent upon the supply of methyl donors provided by folate and 71 
the metabolically-related B vitamins via the formation of S-adenosylmethionine (SAM) 72 
within one-carbon metabolism (5). SAM is the universal methyl donor required for the 73 
methylation of numerous endogenous substances and the maintenance of DNA methylation 74 
(12). Most previous epigenetic studies in humans have used a candidate gene approach to link 75 
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maternal status of folate or other one-carbon nutrients with offspring DNA methylation, and 76 
reported significant associations at specific loci, including the high copy-number 77 
retrotransposon LINE-1, the imprinted genes IGF2 and PEG3 and the metastable epiallele 78 
RBM46 (13,14). As shown by ourselves (15) and others (16), these imprinted genes and 79 
metastable epiallele have the advantage of showing equivalent methylation levels across 80 
various tissues and are potentially responsive to early-life nutritional inputs. In addition, a 81 
meta-analysis of two epigenome-wide association studies (EWAS) investigating the impact of 82 
maternal folate on DNA methylation identified 48 CpGs showing genome-wide significance 83 
(after Bonferroni correction) including clusters of sites at APC2 and OPCML (17).  Previous 84 
studies in the area, however, are observational and thus, by design, cannot provide evidence 85 
of a direct link between maternal folate during pregnancy and DNA methylation effects in 86 
offspring. Apart from the aforementioned genes identified in previous studies, three other 87 
brain related targets known to be regulated by methylation and not previously investigated in 88 
relation to folate, could be of potential interest.  These are: GRB10, an imprinted gene 89 
paternally expressed in the brain (18); GRIN3B, a transiently imprinted gene regulated by 90 
methylation and important for neuronal plasticity during development (19) and BDNF, an 91 
important neurotrophic factor frequently associated with epigenetic modulation (20). 92 
Therefore, the aim of this study was to investigate the effect of FA supplementation 93 
during trimesters 2 and 3 on DNA methylation in cord blood of key epigenetically-controlled 94 
genes, many related to brain development and function.  95 
 96 
METHODS 97 
Participants and Study Design 98 
Samples for the current investigation were made available from a previous double-99 
blinded randomized controlled trial (RCT) in pregnancy of Folic Acid Supplementation 100 
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during the Second and Third Trimesters (FASSTT) conducted in 2005-2006 (Figure 1). The 101 
methodological details of the FASSTT trial have been described in full elsewhere (9). In 102 
summary, healthy pregnant women aged 18-35 y with a singleton pregnancy were recruited at 103 
the 14th gestational week from antenatal clinics at the Causeway Hospital, Coleraine, Northern 104 
Ireland. Women included in the study had taken FA supplements at the recommended dose 105 
(400µg/d) during the first trimester of pregnancy. Women were excluded from the trial if they 106 
had not taken FA during the first trimester or had taken FA at a dose >400 µg/d, were taking 107 
medications known to interfere with B-vitamin metabolism, had undergone in vitro 108 
fertilization treatment, or had a previous NTD-affected pregnancy. Although current practice 109 
in Northern Ireland (UK) is to recommend FA supplements from pre-conception to the end of 110 
the first trimester of pregnancy only, we also excluded from participation any woman who 111 
intended to continue taking FA throughout pregnancy. On recruitment, information on 112 
micronutrient supplementation was collected, with a particular emphasis on the dose and 113 
timing of use of FA supplements. 114 
As previously described, for randomization purposes, FASSTT trial participants at the 115 
beginning of the second trimester were stratified into tertiles of homocysteine concentrations 116 
(from the blood sample taken at recruitment), and women in each stratum were then randomly 117 
assigned to receive either 400 µg FA/d or placebo from the 14th gestational week until the end 118 
of pregnancy (9). The randomization process was carried out by a staff member who was not 119 
involved in the study, and this approach ensured that both researchers and participants were 120 
blinded to the treatment group allocations. Maternal non-fasting blood samples were taken at 121 
the 14th (pre-intervention) and 36th (representative of post-intervention) gestational week, with 122 
corresponding cord blood samples collected at delivery. The birth weight, birth length, head 123 
circumference, mode of delivery and Apgar score for the newborns were collected after 124 
delivery. Ethical approval was obtained from the Office for Research Ethics Committees 125 
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Northern Ireland (05/Q2008/21), and all participants gave written informed consent at the 126 
time of recruitment. 127 
B-vitamin Status Biomarkers 128 
Upon collection, all blood samples were kept at 4℃. They were subsequently 129 
processed within 4 h (apart from cord blood samples which were processed within 24 h of 130 
collection) and stored at -80°C until required for analysis. Serum and red blood cell (RBC) 131 
folate (21) and serum vitamin B-12 (22) were measured by microbiological assay using 132 
established methods. Samples were analyzed blind for all assays, and quality control was 133 
carried out by repeated analysis of stored batches of pooled samples covering a wide range of 134 
values. Intra- and interassay CVs were ≤8.2% for RBC folate and ≤10.4% for serum vitamin 135 
B-12. Methylenetetrahydrofolate reductase (MTHFR) 677C>T genotype was identified by 136 
using polymerase chain reaction amplification followed by HinF1 restriction digestion (23).  137 
DNA Methylation Analysis 138 
Table 1 summarizes the candidate genes selected for methylation analysis and their 139 
function.  For the current analysis, genomic DNA was extracted from cord blood using the 140 
QiAMP DNA Blood Mini kit (Qiagen, Crawley, UK) according to the manufacturer’s 141 
instructions. The quality of DNA was evaluated via gel electrophoresis, and then quantified 142 
using the Nanodrop 2000 spectrophotometer (Labtech International, Ringmer, UK). The DNA 143 
was bisulfite converted using the EpiTect Bisulfite Kit (Qiagen, Crawley, UK) according to 144 
the manufacturer’s instructions. Pyrosequencing assays were designed in-house for all genes 145 
using PyroMark Assay Design Software 2.0 (Qiagen, Crawley, UK) according to previously 146 
published primer sets/regions: Long-interspersed nuclear element-1 (LINE-1) (24), RNA 147 
binding motif protein-46 (RBM46) (14), Paternally-expressed gene 3 (PEG3) (25), Insulin-148 
like growth factor-2 (IGF2) (26), Growth Factor Receptor Bound Protein 10 (GRB10) (27), 149 
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Glutamate Ionotropic Receptor NMDA Type Subunit 3B (GRIN3B) (15, 19), Opioid Binding 150 
Protein/Cell Adhesion Molecule-Like (OPCML) and Adenomatosis Polyposis Coli-2 (APC2) 151 
(17). Brain-derived neurotrophic factor (BDNF) was purchased as a commercially available 152 
assay (Qiagen, Crawley, UK).  153 
Pyrosequencing analysis was carried out in duplicate and overall methylation was 154 
obtained from 5-17 CpG sites for each gene (Supplemental Table 1). Further information on 155 
chromosomal position, primer sequences and number of CpG sites analyzed are detailed in 156 
Supplemental Table 1. Bisulfite converted DNA was amplified using the PyroMark PCR kit 157 
(Qiagen, Crawley, UK) with aforementioned primer sets, conditions were: 15 minutes at 158 
95°C, followed by 45 cycles of 30 seconds at 94°C, 30 seconds at 56°C and 30 seconds at 159 
72°C, with final elongation for 10 minutes at 72°C. Products were verified via gel 160 
electrophoresis prior to pyrosequencing analysis, which was performed using the PyroMark 161 
Q24 Pyrosequencing platform as per manufacturer’s recommendations (Qiagen, Crawley, 162 
UK). 163 
Dietary Analysis 164 
Maternal dietary information was collected during the second trimester of pregnancy 165 
using a 4-d food diary in combination with a food-frequency questionnaire, a method 166 
previously validated for folate and related B-vitamin intakes against biomarker values, as 167 
detailed elsewhere (31). Dietary analysis was carried out using the nutritional software 168 
package WISP version 3.0 (Tinuviel Software), which had been customized to generate 169 
separate values for naturally occurring food folate and FA added to foods; the separate values 170 
were then used to calculate dietary folate equivalents, as previously described (31).   171 
Statistical Analysis  172 
Statistical analysis was performed using the Statistical Package for the Social Sciences 173 
software (SPSS) (Version 22.0; SPSS UK Ltd., Chertsey, UK). The results are expressed as 174 
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mean ± SD, except where otherwise stated. For normalization purposes, variables were log 175 
transformed before analysis, as appropriate. Differences between treatment groups for 176 
participant characteristics were assessed using an independent t test for continuous variables 177 
or chi-square for categorical variables. Differences in gene-specific DNA methylation 178 
between the two treatment groups were assessed by analysis of covariance (ANCOVA) with 179 
adjustment for confounders previously reported to influence DNA methylation such as 180 
maternal age, smoking during pregnancy, caesarean section, baby’s sex and gestational 181 
weight. Multiple linear regression analysis was used to examine the maternal and neonatal 182 
predictors of gene-specific DNA methylation in cord blood (dependent variable) controlling 183 
for common confounders. P<0.05 was considered significant.   184 
 185 
RESULTS 186 
From the total FASSTT trial sample of 119 participants, 86 cord blood samples were 187 
available for the current analysis (9). A comparison of maternal folate status post-intervention 188 
between the sub-cohort with (n = 86) versus without (n = 33) available cord blood, showed no 189 
significant differences in mean (± SD) RBC folate concentrations (1270 ± 611 nmol/L vs 1279 190 
± 820 nmol/L; P = 0.942), ensuring that there was no selection bias in the sub-cohort who 191 
provided cord blood. 192 
At baseline (14th GW), there were no detectable differences between the treatment 193 
groups in general maternal or neonatal characteristics, serum or RBC folate concentrations or 194 
dietary folate (Table 2). As a result of treatment with FA during trimesters 2 and 3, maternal 195 
serum and RBC folate were significantly increased. Cord serum and RBC folate 196 
concentrations were also significantly higher in infants of mothers supplemented with FA 197 
compared with those from the placebo mothers. As expected, maternal RBC folate (at the 36th 198 
GW) was highly correlated with cord RBC folate (r = 0.619; P = <0.001; data not shown).  199 
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DNA methylation levels of the investigated genes in cord blood samples are presented 200 
in Figure 2. The results showed significantly lower overall DNA methylation levels at LINE-201 
1, IGF2 (Figure 2) and BDNF in the offspring of mothers who received FA treatment 202 
compared to placebo during pregnancy (BDNF: Placebo 3.1 ± 0.08 % vs FA 2.7 ± 0.07 %; P 203 
= 0.003; data not shown), after adjustment for maternal age, smoking during pregnancy, 204 
caesarean section, baby’s sex and birth weight. The effect of FA treatment on DNA 205 
methylation was however significant only in female offspring for IGF2 and only in males for 206 
BDNF (Table 3). No other genes showed significant treatment effects for overall DNA 207 
methylation levels. When examined separately, individual CpG sites reflected the overall 208 
DNA methylation lowering effect of FA found with the complete loci, apart from GRB10 209 
CpG 3 where FA supplementation resulted in significantly higher DNA methylation (Table 210 
3). 211 
Multiple linear regression analysis was conducted on the whole cohort (placebo and 212 
FA treated groups combined) in order to identify the maternal and neonatal determinants of 213 
DNA methylation in cord blood (Table 4). Maternal FA treatment was significantly 214 
associated with offspring DNA methylation at LINE-1, IGF2 and BDNF genes, whereas 215 
caesarean section was a determinant of LINE-1 and BDNF methylation. Vitamin B12 216 
concentration in cord (but not maternal) blood was significantly associated with offspring 217 
IGF2 methylation. Neither maternal age nor smoking during pregnancy was significantly 218 
related to DNA methylation in the cord blood of any genes examined.  219 
 220 
DISCUSSION 221 
This is the first randomized trial of FA supplementation during pregnancy to examine 222 
DNA methylation levels in cord blood at a number of important candidate genes, some 223 
previously associated with brain development and function. The results showed significantly 224 
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lower DNA methylation levels of specific genes, IGF2, BDNF and LINE-1, in cord blood 225 
from mothers who received FA supplementation compared with placebo during the second 226 
and third trimesters of pregnancy. In addition, sex-specific differences in the response to FA 227 
were observed in offspring DNA methylation of IGF2 and BDNF. Not only does the current 228 
study present data on relevant genes not previously investigated, but because of the 229 
randomized trial design, the findings can clarify the nature of the relationship between 230 
maternal folate and offspring DNA methylation as reported in previous observational studies. 231 
The significant effect of folate during pregnancy on gene-specific DNA methylation in 232 
cord blood shown here is in broad agreement with the findings of two observational studies 233 
(13,17). The first of these was a large cohort study (n = 913) that found lower methylation in 234 
cord blood for both LINE-1 and PEG3, but higher methylation in IGF2, in women who 235 
reported using FA supplements after the 12th GW of pregnancy (13). Our data showing 236 
significantly lower LINE-1 methylation in response to FA intervention supports this 237 
previously reported relationship with maternal folate; however, our results in relation to the 238 
effect of FA on PEG3 (i.e. no methylation change) and IGF2 (i.e. decrease in methylation) 239 
differ from these earlier observations (13). Of perhaps greater relevance, our results are in 240 
good agreement with the findings of an epigenome-wide meta-analysis (n = 1988) which 241 
found that with increasing maternal folate concentrations (as measured in mid pregnancy; 13th 242 
to 18th GW), there were more CpGs with significantly decreased methylation (416 or 94%) 243 
than those with increased methylation (27 or 6%) (17). Likewise, we showed that in response 244 
to FA intervention during a similar period of pregnancy, more CpG sites have decreases than 245 
increases in methylation at the single-copy loci and at LINE-1, which indicates a genome-246 
wide methylation decrease, since there are >500,000 copies of this element across the genome 247 
(32). Taken together, the current and earlier evidence (17) strongly suggests that the overall 248 
effect of maternal folate is to lower, not increase, DNA methylation. The latter report found 249 
12 
 
 
 
that the largest number of statistically significant CpG sites were within the APC2 gene 250 
(expressed in fetal and adult brain) and the OPCML gene (17). Our results, somewhat 251 
unexpectedly however, showed no significant effect of maternal FA supplementation on DNA 252 
methylation for either APC2 or OPCML (at any CpG sites investigated), an inconsistency that 253 
may relate to differences in the selection of specific CpG sites or to study design differences. 254 
Furthermore, time of sampling for maternal folate measurement was not directly comparable, 255 
with blood samples collected on either the 13th or 18th GW in the previous study (17) whereas 256 
blood samples in the current study represented before and after intervention with FA over 22 257 
weeks of pregnancy from the 14th GW. 258 
The current and aforementioned studies relate to mid-pregnancy onwards, whereas 259 
early pregnancy is considered a sensitive period of plasticity in fetal developmental 260 
programming and has thus been of interest for several epigenetic studies of maternal diet and 261 
offspring DNA methylation in specific genes (5). One such study, showing that maternal 262 
periconceptional FA use (as reported by mothers) was associated with increased methylation 263 
of IGF2 (by 4.5%) in the offspring when measured at 17 months old (33), is at odds with the 264 
current results showing a decrease at this locus in response to FA intervention. In addition, 265 
one notable previous study conducted in Gambian women reported that the season of 266 
conception (which reflects variability in nutrient supply) can influence DNA methylation 267 
patterns of the RBM46 gene in the offspring at 2-8 months (14). In contrast, the current study 268 
found no significant effect in offspring RBM46 methylation in response to FA during 269 
trimesters 2 and 3 of pregnancy. The reason for these inconsistencies are unclear, but may 270 
relate to the fact that compared with the current RCT which investigated the effect of FA 271 
administered from the 14th GW to the end of pregnancy, the latter studies were observational 272 
(14, 33) and focused on the periconceptional phase of pregnancy. In addition, the DNA 273 
methylation effects observed in these previous studies were examined up to 17 months after 274 
13 
 
 
 
birth, a period during which factors other than maternal folate during pregnancy may have 275 
influenced the results. The totality of evidence suggests that there are different windows of 276 
susceptibility to maternal changes in the folate-dependent one-carbon pathway, and therefore 277 
periods beyond periconception may have important roles in influencing epigenetic changes in 278 
the offspring. 279 
Although significant, the offspring DNA methylation changes in response to maternal 280 
FA treatment found here are small. The magnitude of change we showed is however in good 281 
agreement with our previous studies showing that small changes affected by drug treatment 282 
can cause transcriptional alterations including at imprinted genes (15, 19).  Additionally, the 283 
small changes that we observed may lead to an altered balance at imprinted loci globally (34). 284 
Like the current study, previous studies have also reported sex-specific differences in DNA 285 
methylation in offspring in response to nutrition. During the Dutch Hunger Winter, when 286 
there was a reduced supply of essential nutrients including folate, IGF2R methylation was 287 
found to be higher by 2.6% in males, whereas DNA methylation of LEP, IL10 and APOC1 288 
was lower by 1.5-2.9%, compared with female offspring (35). Furthermore, periconceptional 289 
micronutrient supplementation of Gambian women was found to lower offspring methylation 290 
in males only for GTL2-DMR_2 (by 6.5%) and in females only for IGF2R-DMR (by 8.6%) 291 
(36). Likewise, the current results showed sex-specific effects of FA treatment for certain 292 
genes, with the reduction in methylation found to be significant in female (for IGF2) or in 293 
male (for BDNF) offspring only. The findings in the current study of sex-differences in DNA 294 
methylation in IGF2 and BDNF in response to FA in pregnancy may be related to the fact that 295 
they are considered estrogen-responsive genes (37, 38), but the mechanisms underlying these 296 
sex-specific effects shown here and elsewhere remain to be elucidated. 297 
Apart from maternal FA treatment, vitamin B12 status and caesarean section delivery 298 
were found to be significant predictors of gene-specific DNA methylation in the offspring 299 
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when regression analysis was conducted on the whole cohort (placebo and FA treated groups 300 
combined). After adjustment for covariates, our results showed that increasing cord blood 301 
vitamin B12 concentration was associated with decreasing IGF2 methylation. The finding that 302 
vitamin B12 may also influence DNA methylation in a similar way to folate is not surprising 303 
as it acts synergistically with folate within the one-carbon metabolic cycle and both vitamins 304 
are required for the generation of SAM (12). Therefore, although the current study focused on 305 
the effects of intervention with FA during pregnancy, our regression results suggest a 306 
mechanism whereby vitamin B12 status during pregnancy may also have a role in influencing 307 
DNA methylation in the offspring. In relation to caesarean section, the current results are in 308 
line with previous evidence that DNA methylation is higher in infants delivered by caesarean 309 
section than by vaginal delivery (39), an effect that may be owing to maladaptive perinatal 310 
stress associated with this type of delivery.  311 
The main strength of this study is that it is a randomized trial and therefore has the 312 
ability to investigate causal links between maternal FA intervention and DNA methylation of 313 
the offspring. However, this study was not without limitations. The candidate gene approach 314 
means that whilst specific genes of potential interest were identified, other genes and CpG 315 
sites not investigated may have been affected by FA supplementation during pregnancy. In 316 
addition, as per the design of the FASSTT trial, whereby participants were included only if 317 
they had taken FA during the first trimester (9), all women received FA periconceptionally 318 
and therefore no conclusions can be made as regards FA responsive epigenetic effects at this 319 
early stage of pregnancy. Finally, since neural tissue could not be obtained, we cannot 320 
exclude the possibility that the DNA methylation changes we observed in blood are not 321 
reflected in the brain, although methylation at imprints (16) and many of the other loci 322 
investigated (12-16, 24-27) are known to be similar across different tissues.  323 
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In conclusion, the current study presents the first evidence from an RCT that 324 
continued FA supplementation after the first trimester of pregnancy affects offspring DNA 325 
methylation of specific genes, including those related to offspring brain. DNA methylation 326 
may thus offer a potential biological mechanism linking maternal folate status with offspring 327 
neurodevelopment. This area of research is still in its infancy and much remains unknown as 328 
to how an individual’s DNA methylation profile is established during early development, the 329 
contributing factors and the long-term health effects. Future studies using an EWAS approach 330 
will be necessary to more fully explore the epigenetic mechanisms explaining the impact of 331 
maternal FA supplementation on offspring cognitive health.  332 
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TABLE 1  
Candidate genes for methylation analysis and their function  
Gene Gene Description Function Reference  
LINE-1 Long interspersed nuclear 
element-1 
 
Highly repeated retrotransposon thus surrogate marker for global DNA methylation.  Beck et al. 2011 (28) 
 
RBM46 RNA Binding Motif Protein 
46 
Metastable epiallele variably expressed due to epigenetic modifications established 
during early development. 
Dominguez-Salas et al. 2014 
(14) 
 
PEG3 Paternally Expressed Gene 3 
 
Maternally imprinted gene implicated in placental development p53-mediated 
apoptosis. 
 
He & Kim. 2014 (29) 
 
IGF2 Insulin Like Growth Factor 2 Maternally imprinted gene required for development and growth.  Chao & D’Amore. 2008 (30) 
 
GRB10 Growth Factor Receptor 
Bound Protein 10 
 
Growth factor receptor-binding protein that both interacts with insulin-like growth-
factor receptors in embryo and mediates social behavior in adult.  
Garfield et al. 2011 (18) 
 
BDNF Brain-Derived Neurotrophic 
Factor 
 
Neurotrophic factor, promotes neuron growth, maturation and survival, shows frequent 
epigenetic alteration. 
Roth & Sweatt. 2011 (20) 
 
GRIN3B Glutamate Ionotropic 
Receptor NMDA Type 
Subunit 3B 
 
cAMP signaling pathway, NMDA receptor found primarily in motor neurons. Irwin et al. 2014 (19) 
 
 
OPCML Opioid Binding Protein/ Cell 
Adhesion Molecule-Like 
 
Associated with neurocognitive conditions. Joubert et al. 2016 (17) 
 
 
APC2 Adenomatosis Polyposis Coli 
2 
Regulation of Wnt signaling pathway. Joubert et al. 2016 (17) 
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TABLE 2 
General characteristics of mother and offspring participants from the FASSTT Trial1 
 Placebo (n = 45) Folic Acid (n = 41) P value1 
Maternal characteristics2    
Age (y) 28.9 ± 3.5 29.4 ± 3.9 0.513 
BMI (kg/m2) 25.2 ± 3.9 24.9 ± 4.6 0.768 
Smoker n (%) 8 (18) 6 (15) 0.693 
Gestation at baseline (wk) 13.7 ± 2.2 14.1 ± 2.4 0.432 
Duration of FA use at baseline (wk) 14.4 ± 10.1 11.9 ± 6.8 0.175 
Parity (n) 1.0 ± 1.1 1.0 ± 1.0 0.915 
Caesarean section n (%) 11 (24) 10 (24) 0.995 
MTHFR 677TT genotype n (%) 5 (11) 2 (5) 0.291 
Dietary Intakes    
Energy (MJ/d) 8.170 ± 1.717 7.732 ± 1.595 0.280 
Dietary Folate Equivalents (µg/d) 364 ± 172 387 ± 152 0.582 
Vitamin B12 (µg/d) 4.1 ± 1.9 3.9 ± 3.9 0.791 
B-vitamin Biomarkers    
Preintervention (14 GW)    
Serum folate (nmol/L) 48.8 ± 19.8 45.8 ± 19.5 0.469 
RBC folate (nmol/L) 1185 ± 765 1181 ± 649 0.978 
Serum B12 (pmol/L) 224 ± 79 217 ± 79 0.601 
Postintervention (36 GW)3    
Serum folate (nmol/L) 23.6 ± 17.9 46.5 ± 24.8 <0.001 
RBC folate (nmol/L) 991 ± 404 1556 ± 658 <0.001 
Serum B12 (pmol/L) 168 ± 51 157 ± 60 0.229 
Neonatal characteristics    
Gestational age (wk) 40.1 ± 1.3 40.0 ± 1.1 0.540 
Sex, Male n (%) 22 (49) 22 (54) 0.659 
Birth weight (g) 3610 ± 475  3557 ± 464 0.601 
Birth length (cm) 51.5 ± 2.6 51.1 ± 2.2 0.499 
Head circumference (cm) 34.9 ± 1.2 34.8 ± 1.4 0.907 
Apgar score at 1 min 8.4 ± 1.1 8.6 ± 0.6 0.269 
Apgar score at 5 min 8.9 ± 0.4 9.0 ± 0.3 0.220 
Breastfed n (%) 15 (33) 14 (34) 0.240 
MTHFR 677TT genotype n (%) 6 (13) 4 (10) 0.605 
Cord Blood B-vitamin Biomarkers    
Serum folate (nmol/L) 68.3 ± 24.8 91.7 ± 36.7 0.004 
RBC folate (nmol/L) 1518 ± 597 1877 ± 701 0.024 
Serum B12 (pmol/L) 276 ± 155 251 ± 107 0.776 
1Differences between groups were assessed using an independent t test (continuous variables) or chi-
square test (categorical variables). Values expressed as means ± SD except where otherwise stated. 
P<0.05 was considered significant. 
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2Maternal characteristics assessed at the 14th gestational week (pre-intervention) unless where 
otherwise stated. 
3Postintervention refers to 36th gestational week.  
Abbreviations: FASSTT, Folic Acid Supplementation in the Second and Third Trimesters; GW, 
gestational week RBC, red blood cell. 
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TABLE 3 
CpG site-specific DNA methylation (LINE-1, IGF2, BDNF, GRB10 and GRIN3B) in cord blood by 
maternal treatment group1 
 Genomic location Placebo (n = 45) Folic Acid (n = 41) P value1 
Maternal RBC folate status (36 GW; nmol/L) 991 ± 404 1556 ± 658 <0.001 
Cord RBC folate status (nmol/L) 1518 ± 597 1877 ± 701 0.024 
Cord DNA methylation (%)    
LINE-12  Promoter    
CpG 1  83.5 ± 4.7 83.6 ± 3.9 0.679 
CpG 2  62.8 ± 3.9 59.9 ± 4.2 0.002 
CpG 3  37.1 ± 2.4 36.4 ± 3.5 0.301 
CpG 4  20.4 ± 3.0 18.9 ± 3.0 0.045 
CpG 5  57.9 ± 4.4 57.3 ± 4.3 0.489 
CpG 6  81.6 ± 2.7 81.7 ± 3.1 0.933 
Overall (all CpG sites) 57.2 ± 2.1 56.3 ± 1.7 0.024 
Males 57.0 ± 2.3 56.5 ± 1.8 0.067 
Females 57.4 ± 2.0 56.1 ± 1.7 0.038 
IGF2  DMR 2 (somatic)3    
CpG 1  43.4 ± 3.7 40.0 ± 5.2 0.001 
CpG 2  47.1 ± 6.5 43.7 ± 6.5 0.017 
CpG 3  54.4 ± 5.9 52.7 ± 5.7 0.102 
CpG 4  50.0 ± 5.8 48.5 ± 5.7 0.190 
CpG 5  68.0 ± 9.2 65.0 ± 6.2 0.071 
CpG 6  42.8 ± 6.3 40.6 ± 4.2 0.050 
CpG 7  52.5 ± 5.8 52.0 ± 6.5 0.428 
Overall (all CpG sites) 51.2 ± 5.1 48.9 ± 4.4 0.021 
Males 50.2 ± 4.6 49.3 ± 3.4 0.201 
Females 52.1 ± 5.5 48.5 ± 5.3 0.028 
BDNF  Exon 1/Promoter    
CpG 1  2.1 ± 0.8 1.6 ± 0.6 0.001 
CpG 2  6.1 ± 1.5 5.8 ± 2.1 0.229 
CpG 3  2.1 ± 0.7 1.6 ± 0.7 <0.001 
CpG 4  3.1 ± 1.1 2.9 ± 1.1 0.301 
CpG 5  1.8 ± 0.8 1.4 ± 0.5 0.003 
Overall (all CpG sites) 3.1 ± 0.8 2.7 ± 0.7 0.003 
Males 3.2 ± 0.8 2.7 ± 0.7 0.012 
Females 2.9 ± 0.7 2.6 ± 0.7 0.212 
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Data are expressed as mean ± SD. All genes were investigated; those showing significant difference 
between treatment groups are shown. 
1Differences between groups were analyzed by ANCOVA adjusting for covariates: maternal age, 
smoking, caesarean section, baby’s sex and gestational weight. P<0.05 was considered significant.  
2Highly-repeated DNA retrotransposon, chromosomal location unavailable. Assay designed from Florea 
et al. (2013). 
3Gametic DMR, inherits methylation from gamete; somatic DMR, methylation acquired during somatic 
development. Gametic DMR often occur at imprint control regions that regulate more than one gene, 
while somatic DMR are usually associated with regulation of the cognate gene only. 
Abbreviations: GW, gestational week; RBC, red blood cell; CpG, cytosine-phosphate-guanine; DMR, 
differentially methylated region.  
 
GRB10   DMR (gametic)3    
CpG 1  82.2 ± 3.1 80.6 ± 3.8 0.041 
CpG 2  84.9 ± 6.8 82.8 ± 5.9 0.198 
CpG 3  59.9 ± 4.8 61.7 ± 2.9 0.022 
CpG 4  59.8 ± 3.7 59.8 ± 3.7 0.973 
CpG 5  77.0 ± 3.6 76.9 ± 3.8 0.929 
CpG 6  61.8 ± 3.9 62.2 ± 2.8 0.586 
CpG 7  88.0 ± 9.2 87.3 ± 7.5 0.781 
CpG 8  59.2 ± 3.7 60.0 ± 3.6 0.400 
Overall (all CpG sites) 71.6 ± 3.4 71.5 ± 3.0 0.903 
Males 70.9 ± 3.9   71.4 ± 3.0 0.442 
Females 72.2 ± 2.9 71.5 ± 3.1 0.278 
GRIN3B   DMR (gametic)3    
CpG 1  97.4 ± 1.3 96.7 ± 1.6 0.023 
CpG 2  81.0 ± 5.4 82.5 ± 5.9 0.247 
CpG 3  98.3 ± 2.0 97.4 ± 2.5 0.101 
CpG 4  58.0 ± 13.0 60.7 ± 16.9 0.424 
CpG 5  93.0 ± 8.1 86.2 ± 18.3 0.030 
Overall (all CpG sites) 85.5 ± 3.9 84.7 ± 6.6 0.471 
Males 84.7 ± 3.8  85.3 ± 6.5 0.806 
Females 86.4 ± 3.8 83.9 ± 6.8 0.179 
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TABLE 4 
Maternal and newborn determinants of DNA methylation in cord blood (n 86)1 
  
Cord DNA Methylation (%) 
 LINE-1
2  IGF2 
 
BDNF 
  β P value 
 β P value  β P value 
Maternal Characteristics   
 
  
 
  
Folic Acid Treatment -0.247 0.029 
 
-0.226 0.020 
 
-0.301 0.006 
Maternal Age 0.114 0.322 
 
0.170 0.137 
 
0.111 0.317 
Smoking in pregnancy 0.141 0.213 
 
-0.080 0.472 
 
-0.136 0.219 
C-section birth 0.230 0.045 
 
-0.006 0.955 
 
0.296 0.008 
Vitamin B12 (36 GW)3 -0.099 0.492 
 
-0.151 0.185 
 
-0.002 0.990 
Neonatal Characteristics   
 
  
 
  
Sex (M) 0.067 0.572 
 
-0.034 0.764 
 
0.111 0.329 
Birth weight -0.197 0.104 
 
-0.095 0.399 
 
-0.094 0.419 
Cord Vitamin B12 0.038 0.790  -0.236 0.030  0.012 0.932 
1Multiple linear regression analysis performed with gene DNA methylation as dependent variable. P<0.05 was considered significant. 
2Regression for cord DNA methylation was performed for each gene with adjustment for significant covariates, as appropriate. All 
genes were investigated; those showing significant relationships (for maternal or neonatal characteristic) are shown. 
336th GW refers to post-intervention. 
Abbreviations: GW, gestational week; RBC, red blood cell. 
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FIGURE LEGENDS 
FIGURE 1. Flowchart showing study design of participants in the FASSTT trial and cord 
blood collection.  
1Reasons for exclusion: withdrawal from study, pregnancy complications, prescribed folic 
acid, fetal death or transferred to a different hospital. For full details, see original report by 
McNulty et al. 2013 (9). 
Abbreviations: FASSTT, Folic Acid Supplementation in the Second and Third Trimesters. 
 
FIGURE 2. Overall DNA methylation (%) at candidate loci in cord blood by maternal 
treatment group.  
Data are expressed as median ± IQR. Differences were analyzed by ANCOVA adjusting for 
maternal age, smoking, caesarean section, baby’s sex and gestational weight. DNA 
methylation results for BDNF not shown in the figure (Placebo: 3.1 ± 0.08 %; Folic Acid: 2.7 
± 0.07 %; P = 0.003). P<0.05 considered significant. 
 
